Short synthetic peptide marketed as a hepatic bioregulator
PRODUCT PROFILE
Livagen
£46.00
Livagen is short synthetic peptide marketed as a hepatic bioregulator. Researchers examine it in relation to liver-cell stress, metabolism and gene-expression hypotheses.
Why it is distinct
A liver-tissue bioregulator concept rather than a systemic metabolic receptor agonist.
- Evidence stageExperimental
- AvailabilityUnavailable
- Batch recordPublished after verification
- DispatchConfirmed at checkout
Out of stock
Ask about availabilityPRODUCT INFORMATION
Clear first. Detailed when needed.
What this material is+
Livagen is short synthetic peptide marketed as a hepatic bioregulator. Researchers examine it in relation to liver-cell stress, metabolism and gene-expression hypotheses.
Research focus+
Researchers study possible effects on cell stress, metabolism and gene activity. Reliable independent human evidence is limited.
How the mechanism differs+
Proposed liver-directed gene regulation is based mainly on regional experimental literature.
Evidence and limitations+
Sparse independently replicated evidence; clinical effectiveness and a defined molecular target are not established.
Testing and batch documentation+
No live certificate is shown for this staging item. ADINA will only publish a batch document after the product identifier, test method and result have been checked.
RESEARCH PROFILE
Understand the distinction.
Researchers study possible effects on cell stress, metabolism and gene activity. Reliable independent human evidence is limited.
Proposed liver-directed gene regulation is based mainly on regional experimental literature.
A liver-tissue bioregulator concept rather than a systemic metabolic receptor agonist.
Sparse independently replicated evidence; clinical effectiveness and a defined molecular target are not established.
Educational research context only. This information is not dosage, administration or personal-use guidance.
CONTINUE EXPLORING
Related research perspectives.
Selected for useful comparison across neighbouring or contrasting research areas—not as combined-use guidance.
-
Preclinical
FOXO4-DRI
£92.0010 mgBatch file pendingA targeted experimental senolytic mechanism, not a mitochondrial support or endocrine peptide.
UnavailableAsk about availability -
Experimental
Endoluten
£46.0020 mgBatch file pendingPineal/circadian branding with uncertain composition, distinct from sequence-defined Epithalon.
UnavailableAsk about availability -
Preclinical
Epithalon
£58.0010 mgBatch file pendingA proposed pineal-derived bioregulator with telomere-focused claims, not a mitochondrial-targeting peptide.
UnavailableAsk about availability -
Experimental
Vesugen
£46.0020 mgBatch file pendingVascular-tissue focus distinguishes it from mitochondrial or general healthy-ageing peptides.
UnavailableAsk about availability